The FDA approved Neurocrine’s & AbbVie’s Endometriosis drug, Orilissa. Neurocrine stock met & surpassed the Prohost 2018 target

AbbVie (NYSE: ABBV), in cooperation with Neurocrine Biosciences (NBIX), announced that the United States FDA approved Orilissa™ (elagolix) under priority review for women with moderate to severe endometriosis pain. Orilissa represents the first FDA-approved oral treatment for moderate to severe endometriosis pain in over a decade.

The drug is expected to be available in U.S. retail pharmacies in early August 2018.

Endometriosis is a condition where the endometrium, which lines the inside of the uterus grows outside of it. Endometriosis most commonly involves the ovaries, fallopian . . .

This content is for paid subscribers.
Please click here to subscribe or here to log in.